NHRC asks AIIMS to respond on drugs trial on babies

Image
Press Trust of India New Delhi
Last Updated : Jan 19 2013 | 10:47 PM IST

The National Human Rights Commission today asked the All India Institute of Medical Sciences (AIIMS) to respond within four weeks to a complaint filed by an NGO against reported use of drugs meant for adults on children during clinical trials.     

Falling short of issuing a notice, the NHRC forwarded the complaint registered by an NGO to the AIIMS, seeking its comments on the issue.     

"The NHRC has forwarded the complaint to the AIIMS Director, besides the Secretary, Ministry of Health and asked them to send their comments within four weeks," an NHRC official said.     

The NGO, whose RTI query had led to the startling disclosures about clinical trial deaths at AIIMS, sought the intervention of NHRC in the case following reports that adult drugs had been tried on babies at the premier medical institute.     

In the petition submitted to NHRC, Uday Foundation invoked the violation of right to life contained in Article 21 of the constitution.     

It was revealed last week that 49 children died during clinical trials of new medicines in AIIMS over the last two and a half years.

A total of 4,142 children, of whom 2,728 were under the age of one, were enrolled for the trials of new drugs and therapies by the Department of Pediatrics since January one, 2006.      

Reports also suggested that children involved in clinical trials mostly belonged to the weaker sections of society.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 27 2008 | 6:08 PM IST

Next Story